BACKGROUND: Prothrombin complex concentrates (PCC) are currently used to treat congenital or acquired coagulation factor deficiency. In case of serious bleeding caused by new oral anticoagulant agents, reversing treatment with PCC is under debate. PCC preparations mostly contain heparin to prevent thromboembolic events. In factor VIII and IX deficient plasma, Takeyama et al. observed in vitro a heparin effect at appropriate concentrations of PCCs. The aim of the present experiment was to investigate the heparin effect of four factor-PCC at clinically relevant concentrations in whole blood. In an in vitro experiment, we compared the PCC preparation used in the experiments of Takeyama with a high heparin content to a new heparin-free PCC preparation. METHOD: After ethics committee approval and written informed consent, the citrated whole blood was obtained from ten healthy volunteers. We tested heparin-containing Prothromplex(®) and heparin-free Cofact(®) at concentrations of 0.31, 0.63, and 1.25 IU/ml. Protamine was added to another set of samples (1:1 heparin:protamine). We used the NATEM test in the rotational thromboelastometer ROTEM(®). RESULTS: In the heparin PCC preparation, we observed a significant (p < 0.001) concentration-dependent prolongation in CT and CFT, even at the lowest concentration. MCF was also significantly reduced. The heparin effect was reversible by protamine. The heparin-free PCC did not affect the onset of coagulation. The interpretation of the alpha-angle showed no increased thrombus formation in heparin-free PCC preparation. CONCLUSION: Our results extend the report of Takeyama et al. At clinically relevant PCC concentrations, the heparin effect was significant in thromboelastometry. The heparin content of PCCs should be considered in clinical routine.
BACKGROUND: Prothrombin complex concentrates (PCC) are currently used to treat congenital or acquired coagulation factor deficiency. In case of serious bleeding caused by new oral anticoagulant agents, reversing treatment with PCC is under debate. PCC preparations mostly contain heparin to prevent thromboembolic events. In factor VIII and IX deficient plasma, Takeyama et al. observed in vitro a heparin effect at appropriate concentrations of PCCs. The aim of the present experiment was to investigate the heparin effect of four factor-PCC at clinically relevant concentrations in whole blood. In an in vitro experiment, we compared the PCC preparation used in the experiments of Takeyama with a high heparin content to a new heparin-free PCC preparation. METHOD: After ethics committee approval and written informed consent, the citrated whole blood was obtained from ten healthy volunteers. We tested heparin-containing Prothromplex(®) and heparin-free Cofact(®) at concentrations of 0.31, 0.63, and 1.25 IU/ml. Protamine was added to another set of samples (1:1 heparin:protamine). We used the NATEM test in the rotational thromboelastometer ROTEM(®). RESULTS: In the heparin PCC preparation, we observed a significant (p < 0.001) concentration-dependent prolongation in CT and CFT, even at the lowest concentration. MCF was also significantly reduced. The heparin effect was reversible by protamine. The heparin-free PCC did not affect the onset of coagulation. The interpretation of the alpha-angle showed no increased thrombus formation in heparin-free PCC preparation. CONCLUSION: Our results extend the report of Takeyama et al. At clinically relevant PCC concentrations, the heparin effect was significant in thromboelastometry. The heparin content of PCCs should be considered in clinical routine.
Authors: Lonneke van Aart; Heleen W Eijkhout; Jan S Kamphuis; Marco Dam; Marinus Eeftinck Schattenkerk; Teunis J Schouten; Ben Ploeger; Paul F W Strengers Journal: Thromb Res Date: 2005-09-21 Impact factor: 3.944
Authors: Herbert Schöchl; Cristina Solomon; Arthur Schulz; Wolfgang Voelckel; Alexander Hanke; Martijn Van Griensven; Heinz Redl; Soheyl Bahrami Journal: Mol Med Date: 2010-12-14 Impact factor: 6.354
Authors: M Mittermayr; J Margreiter; C Velik-Salchner; A Klingler; W Streif; D Fries; P Innerhofer Journal: Br J Anaesth Date: 2005-07-15 Impact factor: 9.166
Authors: Harry R Buller; Anthonie W A Lensing; Martin H Prins; Giancarlo Agnelli; Alexander Cohen; Alexander S Gallus; Frank Misselwitz; Gary Raskob; Sebastian Schellong; Annelise Segers Journal: Blood Date: 2008-07-11 Impact factor: 22.113
Authors: Martin Ponschab; Wolfgang Voelckel; Michaela Pavelka; Christoph J Schlimp; Herbert Schöchl Journal: Scand J Trauma Resusc Emerg Med Date: 2015-10-29 Impact factor: 2.953
Authors: Johannes Gratz; Christoph J Schlimp; Markus Honickel; Nadine Hochhausen; Herbert Schöchl; Oliver Grottke Journal: J Clin Med Date: 2020-11-25 Impact factor: 4.241
Authors: Oliver Grottke; Rolf Rossaint; Yvonne Henskens; Rene van Oerle; Hugo Ten Cate; Henri M H Spronk Journal: PLoS One Date: 2013-05-17 Impact factor: 3.240